CymaBay Investor Sues For Books On $4.3B Gilead Merger

By Sydney Price · March 21, 2024, 8:03 PM EDT

A shareholder of liver disease-focused biopharmaceutical company CymaBay Therapeutics Inc. sued the company in Delaware Chancery Court to extract more information over a proposed $4.3 billion merger with Gilead Sciences Inc.,...

To view the full article, register now.